1
|
Bernstein M, Kovar H, Paulussen M, Randall
RL, Schuck A, Teot LA and Juergens H: Ewings sarcoma family of
tumors: Current management. Oncologist. 11:503–519. 2006.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Riggi N and Stamenkovic I: The biology of
Ewing sarcoma. Cancer Lett. 254:1–10. 2007. View Article : Google Scholar : PubMed/NCBI
|
3
|
Campanacci M: Ewings sarcoma, primitive
neuroectodermal tumor (PNET)Bone and Soft Tissue Tumors. 2nd
edition. Springer-Verlag; Wien, Vienna: pp. 653–682. 1999,
View Article : Google Scholar
|
4
|
Paulussen M, Craft AW, Lewis I, Hackshaw
A, Douglas C, Dunst J, Schuck A, Winkelmann W, Köhler G, Poremba C,
et al: European Intergroup Cooperative Ewings Sarcoma Study-92:
Results of the EICESS-92 Study: Two randomized trials of Ewings
sarcoma treatment - cyclophosphamide compared with ifosfamide in
standard-risk patients and assessment of benefit of etoposide added
to standard treatment in high-risk patients. J Clin Oncol.
26:4385–4393. 2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
Luksch R, Tienghi A, Hall KS, Fagioli F,
Picci P, Barbieri E, Gandola L, Eriksson M, Ruggieri P, Daolio P,
et al: Primary metastatic Ewings family tumors: Results of the
Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV
Study including myeloablative chemotherapy and total-lung
irradiation. Ann Oncol. 23:2970–2976. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Amano M, Nakayama M and Kaibuchi K:
Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell
polarity. Cytoskeleton. 67:545–554. 2010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Wong CCL, Wong CM, Tung EKK, Man K and Ng
IOL: Rho-kinase 2 is frequently overexpressed in hepatocellular
carcinoma and involved in tumor invasion. Hepatology. 49:1583–1594.
2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Liu X, Choy E, Hornicek FJ, Yang S, Yang
C, Harmon D, Mankin H and Duan Z: ROCK1 as a potential therapeutic
target in osteosarcoma. J Orthop Res. 29:1259–1266. 2011.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Lane J, Martin TA, Watkins G, Mansel RE
and Jiang WG: The expression and prognostic value of ROCK I and
ROCK II and their role in human breast cancer. Int J Oncol.
33:585–593. 2008.PubMed/NCBI
|
10
|
Kamai T, Yamanishi T, Shirataki H, Takagi
K, Asami H, Ito Y and Yoshida K: Overexpression of RhoA, Rac1, and
Cdc42 GTPases is associated with progression in testicular cancer.
Clin Cancer Res. 10:4799–4805. 2004. View Article : Google Scholar : PubMed/NCBI
|
11
|
Vishnubhotla R, Sun S, Huq J, Bulic M,
Ramesh A, Guzman G, Cho M and Glover SC: ROCK-II mediates colon
cancer invasion via regulation of MMP-2 and MMP-13 at the site of
invadopodia as revealed by multiphoton imaging. Lab Invest.
87:1149–1158. 2007. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kamai T, Tsujii T, Arai K, Takagi K, Asami
H, Ito Y and Oshima H: Significant association of Rho/ROCK pathway
with invasion and metastasis of bladder cancer. Clin Cancer Res.
9:2632–26412003.
|
13
|
Zhang C, Zhang S, Zhang Z, He J, Xu Y and
Liu S: ROCK has a crucial role in regulating prostate tumor growth
through interaction with c-Myc. Oncogene. 33:5582–5591. 2014.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Wang N, Feng Y, Lau EP, Tsang C, Ching Y,
Man K, Tong Y, Nagamatsu T, Su W and Tsao S: F-Actin reorganization
and inactivation of Rho signaling pathway involved in the
inhibitory effect of Coptidis Rhizoma on hepatoma cell migration.
Integr Cancer Ther. 9:354–364. 2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Patel RA, Liu Y, Wang B, Li R and Sebti
SM: Identification of novel ROCK inhibitors with anti-migratory and
anti-invasive activities. Oncogene. 33:550–555. 2014. View Article : Google Scholar : PubMed/NCBI
|
16
|
Yoneda A, Multhaupt HA and Couchman JR:
The Rho kinases I and II regulate different aspects of myosin II
activity. J Cell Biol. 170:443–453. 2005. View Article : Google Scholar : PubMed/NCBI
|
17
|
Yoneda A, Ushakov D, Multhaupt HAB and
Couchman JR: Fibronectin matrix assembly requires distinct
contributions from Rho kinases I and -II. Mol Biol Cell. 18:66–75.
2007. View Article : Google Scholar : PubMed/NCBI
|
18
|
Mertsch S and Thanos S: Opposing signaling
of ROCK1 and ROCK2 determines the switching of substrate
specificity and the mode of migration of glioblastoma cells. Mol
Neurobiol. 49:900–915. 2014. View Article : Google Scholar : PubMed/NCBI
|
19
|
Kovar H, Pospisilova S, Jug G, Printz D
and Gadner H: Response of Ewing tumor cells to forced and activated
p53 expression. Oncogene. 22:3193–3204. 2003. View Article : Google Scholar : PubMed/NCBI
|
20
|
Bagnara GP, Serra M, Giovannini M, Badiali
M, Stella M, Montaldi A, Granchi D, Paolucci P, Rocchi P, Pession
A, et al: Establishment and characterization of a primitive
neuroectodermal tumor of bone continuous cell line (LAP-35). Int J
Cell Cloning. 8:409–424. 1990. View Article : Google Scholar : PubMed/NCBI
|
21
|
Zucchini C, Manara MC, Pinca RS, De
Sanctis P, Guerzoni C, Sciandra M, Lollini PL, Cenacchi G, Picci P,
Valvassori L, et al: CD99 suppresses osteosarcoma cell migration
through inhibition of ROCK2 activity. Oncogene. 33:1912–1921. 2014.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Manara MC, Bernard G, Lollini PL, Nanni P,
Zuntini M, Landuzzi L, Benini S, Lattanzi G, Sciandra M, Serra M,
et al: CD99 acts as an oncosuppressor in osteosarcoma. Mol Biol
Cell. 17:1910–1921. 2006. View Article : Google Scholar : PubMed/NCBI
|
23
|
Yang P, Wen HZ and Zhang JH: Expression of
a dominant-negative Rho-kinase promotes neurite outgrowth in a
microenvironment mimicking injured central nervous system. Acta
Pharmacol Sin. 31:531–539. 2010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Cordenonsi M, Zanconato F, Azzolin L,
Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR,
Poletti A, et al: The Hippo transducer TAZ confers cancer stem
cell-related traits on breast cancer cells. Cell. 147:759–772.
2011. View Article : Google Scholar : PubMed/NCBI
|
25
|
Dupont S, Morsut L, Aragona M, Enzo E,
Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M,
Bicciato S, et al: Role of YAP/TAZ in mechanotransduction. Nature.
474:179–183. 2011. View Article : Google Scholar : PubMed/NCBI
|
26
|
Aragona M, Panciera T, Manfrin A, Giulitti
S, Michielin F, Elvassore N, Dupont S and Piccolo S: A mechanical
checkpoint controls multicellular growth through YAP/TAZ regulation
by actin-processing factors. Cell. 154:1047–1059. 2013. View Article : Google Scholar : PubMed/NCBI
|
27
|
Chen CS, Mrksich M, Huang S, Whitesides GM
and Ingber DE: Geometric control of cell life and death. Science.
276:1425–1428. 2008. View Article : Google Scholar
|
28
|
Sero JE, Thodeti CK, Mammoto A, Bakal C,
Thomas S and Ingber DE: Paxillin mediates sensing of physical cues
and regulates directional cell motility by controlling lamellipodia
positioning. PLoS One. 6:e283032011. View Article : Google Scholar : PubMed/NCBI
|
29
|
Mcbeath R, Pirone DM, Nelson CM,
Bhadriraju K and Chen CS: Cell shape, cytoskeletal tension, and
RhoA regulate stem cell lineage commitment. Dev Cell. 6:483–495.
2004. View Article : Google Scholar : PubMed/NCBI
|
30
|
Discher DE, Mooney DJ and Zandstra PW:
Growth factors, matrices, and forces combine and control stem
cells. Science. 324:1673–1677. 2009. View Article : Google Scholar : PubMed/NCBI
|
31
|
Julian L and Olson MF: Rho-associated
coiled-coil containing kinases (ROCK): Structure, regulation, and
functions. Small GTPases. 5:e298462014. View Article : Google Scholar : PubMed/NCBI
|
32
|
Charytonowicz E, Terry M, Coakley K, Telis
L, Remotti F, Cordon-Cardo C, Taub RN and Matushansky I: PPARγ
agonists enhance ET-743-induced adipogenic differentiation in a
transgenic mouse model of myxoid round cell liposarcoma. J Clin
Invest. 122:886–898. 2012. View
Article : Google Scholar : PubMed/NCBI
|
33
|
Liu X, Zhang Z, Yan X, Liu H, Zhang L, Yao
A, Guo C, Liu X and Xu T: The Rho kinase inhibitor Y-27632
facilitates the differentiation of bone marrow mesenchymal stem
cells. J Mol Histol. 45:707–714. 2014. View Article : Google Scholar : PubMed/NCBI
|